Minhe Shen

973 total citations
36 papers, 736 citations indexed

About

Minhe Shen is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Minhe Shen has authored 36 papers receiving a total of 736 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 11 papers in Molecular Biology and 10 papers in Cancer Research. Recurrent topics in Minhe Shen's work include Cancer Cells and Metastasis (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer-related molecular mechanisms research (5 papers). Minhe Shen is often cited by papers focused on Cancer Cells and Metastasis (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer-related molecular mechanisms research (5 papers). Minhe Shen collaborates with scholars based in China, United Kingdom and United States. Minhe Shen's co-authors include Shanming Ruan, Leitao Sun, Harpreet Wasan, Jieru Yu, Leyin Zhang, Fangfang Tao, Kaibo Guo, Kai Zhang, Yuan Li and Xinxin Tian and has published in prestigious journals such as PLoS ONE, Scientific Reports and The FASEB Journal.

In The Last Decade

Minhe Shen

36 papers receiving 729 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Minhe Shen China 15 309 300 186 130 102 36 736
Guowang Yang China 17 264 0.9× 317 1.1× 93 0.5× 150 1.2× 63 0.6× 57 812
Virginie Poindessous France 17 282 0.9× 484 1.6× 187 1.0× 123 0.9× 65 0.6× 32 837
Chao Wu China 15 193 0.6× 423 1.4× 263 1.4× 116 0.9× 77 0.8× 62 768
Shuling Huang China 16 278 0.9× 444 1.5× 164 0.9× 147 1.1× 63 0.6× 25 854
Fanhua Kong China 16 130 0.4× 445 1.5× 255 1.4× 119 0.9× 87 0.9× 40 786
Jihong Feng China 20 346 1.1× 696 2.3× 333 1.8× 207 1.6× 140 1.4× 49 1.2k
Wenbin Song China 19 245 0.8× 540 1.8× 213 1.1× 204 1.6× 80 0.8× 36 985
Umar Mehraj India 16 300 1.0× 366 1.2× 154 0.8× 165 1.3× 143 1.4× 24 714

Countries citing papers authored by Minhe Shen

Since Specialization
Citations

This map shows the geographic impact of Minhe Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minhe Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minhe Shen more than expected).

Fields of papers citing papers by Minhe Shen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minhe Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minhe Shen. The network helps show where Minhe Shen may publish in the future.

Co-authorship network of co-authors of Minhe Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Minhe Shen. A scholar is included among the top collaborators of Minhe Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minhe Shen. Minhe Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Guo, Kaibo, Yuqian Feng, Leitao Sun, et al.. (2021). Resveratrol and Its Analogs: Potent Agents to Reverse Epithelial-to-Mesenchymal Transition in Tumors. Frontiers in Oncology. 11. 644134–644134. 25 indexed citations
4.
Jin, Huimin, et al.. (2021). Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?. Frontiers in Pharmacology. 12. 572845–572845. 7 indexed citations
5.
6.
Zhang, Bo, et al.. (2020). Risk of Second Primary Malignancies in Colon Cancer Patients Treated With Colectomy. Frontiers in Oncology. 10. 1154–1154. 13 indexed citations
7.
Sun, Leitao, Leyin Zhang, Jieru Yu, et al.. (2020). Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Scientific Reports. 10(1). 2083–2083. 136 indexed citations
8.
Zhu, Ying, Leitao Sun, Jieru Yu, et al.. (2020). Identification of biomarkers in colon cancer based on bioinformatic analysis. Translational Cancer Research. 9(8). 4879–4895. 12 indexed citations
9.
Sun, Leitao, Leyin Zhang, Kaibo Guo, et al.. (2020). Inhibition to Epithelial-Mesenchymal Transition and Metastatic Potential In Colorectal Cancer Cell By Combination of Traditional Chinese Medicine Formulation Jiedu Sangen Decoction and PD-L1 Inhibitor. Integrative Cancer Therapies. 19. 1872190918–1872190918. 12 indexed citations
10.
Li, Zhaoyi, Huimin Jin, Leitao Sun, et al.. (2019). The Method of Activating Blood and Dredging Collaterals for Reducing Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Evidence-based Complementary and Alternative Medicine. 2019. 1–18. 8 indexed citations
11.
Guo, Kaibo, et al.. (2019). Expression of Protein 4.1 Family in Breast Cancer: Database Mining for 4.1 Family Members in Malignancies. Medical Science Monitor. 25. 3374–3389. 10 indexed citations
12.
Ruan, Shanming, et al.. (2019). VEGF-C in rectal cancer tissues promotes tumor invasion and metastasis.. PubMed. 23(1). 42–47. 9 indexed citations
13.
Zhang, Kai, Leitao Sun, Yuan Li, et al.. (2018). Jiedu Sangen Decoction Inhibits Migration and Invasion of Colon Cancer SW480 Cells via Suppressing Epithelial Mesenchymal Transition. Evidence-based Complementary and Alternative Medicine. 2018(1). 1495768–1495768. 9 indexed citations
14.
Guo, Kaibo, et al.. (2018). Association between the overexpression of Her3 and clinical pathology and prognosis of colorectal cancer. Medicine. 97(37). e12317–e12317. 10 indexed citations
15.
Ruan, Shanming, Zhiqian Zhang, Xinxin Tian, et al.. (2018). Compound Fuling Granule Suppresses Ovarian Cancer Development and Progression by disrupting mitochondrial function, galactose and fatty acid metabolism. Journal of Cancer. 9(18). 3382–3393. 16 indexed citations
16.
Tao, Fangfang, Xinxin Tian, Shanming Ruan, Minhe Shen, & Zhiqian Zhang. (2018). miR‐211 sponges lncRNA MALAT1 to suppress tumor growth and progression through inhibiting PHF19 in ovarian carcinoma. The FASEB Journal. 32(11). 6330–6343. 74 indexed citations
17.
Tao, Fangfang, Ping Lü, Mengmeng Zheng, et al.. (2017). Metabolomics Analysis for Defining Serum Biochemical Markers in Colorectal Cancer Patients with Qi Deficiency Syndrome or Yin Deficiency Syndrome. Evidence-based Complementary and Alternative Medicine. 2017(1). 7382752–7382752. 17 indexed citations
18.
Tao, Fangfang, Shanming Ruan, Wenhong Liu, et al.. (2016). Fuling Granule, a Traditional Chinese Medicine Compound, Suppresses Cell Proliferation and TGFβ-Induced EMT in Ovarian Cancer. PLoS ONE. 11(12). e0168892–e0168892. 18 indexed citations
19.
Zhang, Jie, Minhe Shen, & Shanming Ruan. (2014). [Beta-HIVS combined cisplatin inhibited activities of human ovarian cancer cell line SKOV3 in vitro].. PubMed. 34(8). 987–90. 2 indexed citations
20.
Shen, Minhe, et al.. (2012). Inhibition of Breast Cancer Metastasis Via PITPNM3 by Pachymic Acid. Asian Pacific Journal of Cancer Prevention. 13(5). 1877–1880. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guowang Yang Breakdown of academic impact, for papers by Virginie Poindessous Breakdown of academic impact, for papers by Chao Wu Breakdown of academic impact, for papers by Shuling Huang Breakdown of academic impact, for papers by Fanhua Kong Breakdown of academic impact, for papers by Jihong Feng Breakdown of academic impact, for papers by Wenbin Song Breakdown of academic impact, for papers by Umar Mehraj
Rankless by CCL
2026